Nanoform Reports Strong Growth and Advances in Nanoparticle Drug Development Pipeline
• Nanoform achieved record project signings in 2024 with revenue growth of 87% in Q4, marking a strong recovery after six quarters of decline.
• The company is advancing three key product developments - Nanoenzalutamide, Nanoapalutamide, and Nanoencorafenib - with deal discussions intensifying and expected closures in coming months.
• Nanoenzalutamide's pivotal bioequivalence studies are set to begin in Q2 2025, targeting a 2027/28 market launch as a patient-friendly alternative to Xtandi® with reduced pill burden.
© Copyright 2025. All Rights Reserved by MedPath